Issie Kirby
Stock Analyst at Rothschild & Co Redburn
(1.11)
# 3,845
Out of 5,078 analysts
19
Total ratings
25%
Success rate
-4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMED MiniMed Group | Initiated Coverage: Buy | $30 | $18.34 | +63.58% | 1 | Oct 13, 2026 | |
| PODD Insulet | Downgraded: Hold | $235 → $220 | $149.01 | +47.64% | 2 | Apr 24, 2026 | |
| TNDM Tandem Diabetes Care | Reiterated: Buy | $60 → $45 | $17.43 | +158.18% | 2 | Apr 24, 2026 | |
| SWX: ALC Alcon Inc. | Reiterated: Buy | CHF 93.00 → CHF 77.00 | CHF 57.94 | +32.90% | 4 | Mar 4, 2026 | |
| COO The Cooper Companies | Downgraded: Hold | $125 → $85 | $61.21 | +38.87% | 3 | Mar 4, 2026 | |
| SWX: SOON Sonova Holding AG | Upgraded: Hold | CHF 225.00 → CHF 215.00 | CHF 283.20 | n/a | 4 | Oct 6, 2025 | |
| EPA: EL EssilorLuxottica Société anonyme | Upgraded: Buy | €320.00 | €181.20 | n/a | 1 | Sep 17, 2025 | |
| DXCM DexCom | Upgraded: Buy | $130 → $115 | $77.94 | n/a | 2 | Feb 3, 2025 |
MiniMed Group
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $18.34
Upside: +63.58%
Insulet
Apr 24, 2026
Downgraded: Hold
Price Target: $235 → $220
Current: $149.01
Upside: +47.64%
Tandem Diabetes Care
Apr 24, 2026
Reiterated: Buy
Price Target: $60 → $45
Current: $17.43
Upside: +158.18%
Alcon Inc.
Mar 4, 2026
Reiterated: Buy
Price Target: CHF 93.00 → CHF 77.00
Current: CHF 57.94
Upside: +32.90%
The Cooper Companies
Mar 4, 2026
Downgraded: Hold
Price Target: $125 → $85
Current: $61.21
Upside: +38.87%
Sonova Holding AG
Oct 6, 2025
Upgraded: Hold
Price Target: CHF 225.00 → CHF 215.00
Current: CHF 283.20
Upside: n/a
EssilorLuxottica Société anonyme
Sep 17, 2025
Upgraded: Buy
Price Target: €320.00
Current: €181.20
Upside: n/a
DexCom
Feb 3, 2025
Upgraded: Buy
Price Target: $130 → $115
Current: $77.94
Upside: n/a